|
|
The
standard dose of the protease inhibitor amprenavir requires
individuals to take large numbers of pills. A new formulation
of amprenavir may prove to be as or more effective, requiring
less pills per day. |
|
Objective
|
To
study the safety and effectiveness of the experimental
formulation of amprenavir to see if it is easier to tolerate
and to take. |
|
|
Volunteers
will be randomly assigned to one of two study groups:
Group
1: Volunteers will receive 1335 mg of the new amprenavir
formulation, 200 mg of ritonavir, 300 mg of abacavir
and 150 mg of 3TC.
Group
2: Volunteers will receive 1250 mg of nelfinavir,
300 mg of abacavir and 150 mg of 3TC.
|
|
Inclusion
Criteria
|
•
Two kinds of volunteers are needed:
- Volunteers
who have taken anti-HIV medications for less
than 4 weeks.
- Volunteers
who have never taken anti-HIV medications before.
•
HIV+ male or female at least 18 years old.
•
Viral load greater or equal to than 1000 copies/mL.
•
If female, not pregnant and willing to use a barrier
method of contraception for the duration of the study.
|
|
Status
__
|
Enrolling
--
|
For
more information about participating in this study
in the Los Angeles area, please call 310/358.2429
or e-mail Corie Castro at ccastro@aidsresearch.org
|
|
We
encourage participation by women and people of color.
This
ad was reviewed and approved by the AIDS Research Alliance
Institutional Review Board in April, 2001.
|
